PAVmed, Inc. (PAVM) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1240511,
    "name": "PAVmed, Inc.",
    "stock_name": "PAVmed, Inc.",
    "full_name": "PAVmed, Inc.",
    "name_url": "stocks-analysis/pavmed-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "0.34",
    "chg": 0.01,
    "chgp": "3.58%",
    "dir": 1,
    "prev_price": "0.33",
    "mcapval": "9.27",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US70387R4039",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "703.89 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/pavmed-inc-1240511-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is PAVmed, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-pavmed-inc-overvalued-or-undervalued-3651056",
        "imagepath": "",
        "date": "2025-10-28 11:11:49",
        "description": "As of 24 October 2025, PAVmed, Inc. has moved from an attractive to a fair valuation grade. The company appears to be overvalued based on its current metrics. Key ratios include a Price to Book Value of 0.23, an EV to EBIT of -0.43, and an EV to EBITDA of -0.44, which suggest significant challenges in profitability and valuation relative to its assets.\n\nIn comparison to peers, PAVmed's P/E ratio stands at 0, while Delcath Systems, Inc. is considered expensive with a P/E of 68.06, and Neuronetics, Inc. is risky with a P/E of -5.11. The stark contrast in valuations highlights PAVmed's relative overvaluation in the current market context. Additionally, PAVmed's stock has underperformed significantly against the S&P 500, with a year-to-date return of -34.92% compared to the index's 15.47%, reinforcing concerns about its valuation...."
      },
      {
        "title": "Is PAVmed, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-pavmed-inc-overvalued-or-undervalued-3647564",
        "imagepath": "",
        "date": "2025-10-27 11:12:05",
        "description": "As of 24 October 2025, the valuation grade for PAVmed, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be overvalued given its current metrics, particularly with a P/E ratio of 0, a Price to Book Value of 0.23, and an EV to EBITDA of -0.44. In comparison, Delcath Systems, Inc. is considered expensive with a P/E of 68.06, while Neuronetics, Inc. is classified as risky with a P/E of -5.11, highlighting the relative valuation challenges faced by PAVmed.\n\nThe stock has significantly underperformed against the S&P 500, with a year-to-date return of -34.92% compared to the index's 15.47%. This trend continues over longer periods, with a 1-year return of -59.16% versus the S&P 500's 16.90%. Overall, PAVmed, Inc. is currently overvalued based on its financial ratios and performance relative to its peers and the broader market...."
      },
      {
        "title": "Is PAVmed, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-pavmed-inc-overvalued-or-undervalued-3646106",
        "imagepath": "",
        "date": "2025-10-26 11:08:28",
        "description": "As of 24 October 2025, PAVmed, Inc. has moved from an attractive to a fair valuation grade. The company appears to be overvalued based on its current metrics. Key ratios include a Price to Book Value of 0.23, an EV to EBIT of -0.43, and a ROE of 92.94%. In comparison, Delcath Systems, Inc. is considered expensive with a P/E of 68.06, while BioSig Technologies, Inc. shows a negative EV to EBITDA of -4.99.\n\nThe stock has significantly underperformed relative to the S&P 500, with a year-to-date return of -34.92% compared to the S&P 500's 15.47%. This stark contrast reinforces the notion that PAVmed, Inc. is currently overvalued in the market...."
      },
      {
        "title": "Is PAVmed, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-pavmed-inc-technically-bullish-or-bearish-3546221",
        "imagepath": "",
        "date": "2025-09-20 19:27:19",
        "description": "As of 2 September 2025, the technical trend for PAVmed, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish signal. The Bollinger Bands indicate a mildly bearish trend on the weekly chart and bearish on the monthly. Daily moving averages are bearish, and the KST is bearish weekly but mildly bullish monthly. The Dow Theory suggests a mildly bearish stance on the weekly timeframe with no trend monthly. Despite some mildly bullish signals from the OBV on both weekly and monthly charts, the overall technical picture remains weak.\n\nOver the past year, PAVmed has significantly underperformed the S&P 500, with a return of -74.41% compared to the S&P's 17.14%...."
      },
      {
        "title": "Is PAVmed, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-pavmed-inc-overvalued-or-undervalued-3542831",
        "imagepath": "",
        "date": "2025-09-20 18:03:22",
        "description": "As of 2 September 2025, the valuation grade for PAVmed, Inc. has moved from fair to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued based on its current metrics, particularly with a Price to Book Value of 0.23, an EV to EBIT of -0.43, and an EV to EBITDA of -0.44. In comparison to peers, Delcath Systems, Inc. is considered expensive with a P/E of 68.06, while Neuronetics, Inc. has a risky valuation with a P/E of -5.11, highlighting PAVmed's relatively better positioning.\n\nDespite the attractive valuation, PAVmed has faced significant challenges, as evidenced by its stock performance, which has seen a staggering decline of 98.33% over the past five years compared to a 96.61% increase in the S&P 500. This stark contrast in returns underscores the potential mispricing of the stock, reinforcing the notion that it may be undervalued in the current market ..."
      }
    ],
    "total": 10,
    "sid": "1240511",
    "stock_news_url": "https://www.marketsmojo.com/news/pavmed-inc-1240511"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is PAVmed, Inc. overvalued or undervalued?

2025-10-28 11:11:49

As of 24 October 2025, PAVmed, Inc. has moved from an attractive to a fair valuation grade. The company appears to be overvalued based on its current metrics. Key ratios include a Price to Book Value of 0.23, an EV to EBIT of -0.43, and an EV to EBITDA of -0.44, which suggest significant challenges in profitability and valuation relative to its assets. In comparison to peers, PAVmed's P/E ratio stands at 0, while Delcath Systems, Inc. is considered expensive with a P/E of 68.06, and Neuronetics, Inc. is risky with a P/E of -5.11. The stark contrast in valuations highlights PAVmed's relative overvaluation in the current market context. Additionally, PAVmed's stock has underperformed significantly against the S&P 500, with a year-to-date return of -34.92% compared to the index's 15.47%, reinforcing concerns about its valuation....

Is PAVmed, Inc. overvalued or undervalued?

2025-10-27 11:12:05

As of 24 October 2025, the valuation grade for PAVmed, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be overvalued given its current metrics, particularly with a P/E ratio of 0, a Price to Book Value of 0.23, and an EV to EBITDA of -0.44. In comparison, Delcath Systems, Inc. is considered expensive with a P/E of 68.06, while Neuronetics, Inc. is classified as risky with a P/E of -5.11, highlighting the relative valuation challenges faced by PAVmed. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -34.92% compared to the index's 15.47%. This trend continues over longer periods, with a 1-year return of -59.16% versus the S&P 500's 16.90%. Overall, PAVmed, Inc. is currently overvalued based on its financial ratios and performance relative to its peers and the broader market....

Is PAVmed, Inc. overvalued or undervalued?

2025-10-26 11:08:28

As of 24 October 2025, PAVmed, Inc. has moved from an attractive to a fair valuation grade. The company appears to be overvalued based on its current metrics. Key ratios include a Price to Book Value of 0.23, an EV to EBIT of -0.43, and a ROE of 92.94%. In comparison, Delcath Systems, Inc. is considered expensive with a P/E of 68.06, while BioSig Technologies, Inc. shows a negative EV to EBITDA of -4.99. The stock has significantly underperformed relative to the S&P 500, with a year-to-date return of -34.92% compared to the S&P 500's 15.47%. This stark contrast reinforces the notion that PAVmed, Inc. is currently overvalued in the market....

Is PAVmed, Inc. technically bullish or bearish?

2025-09-20 19:27:19

As of 2 September 2025, the technical trend for PAVmed, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish signal. The Bollinger Bands indicate a mildly bearish trend on the weekly chart and bearish on the monthly. Daily moving averages are bearish, and the KST is bearish weekly but mildly bullish monthly. The Dow Theory suggests a mildly bearish stance on the weekly timeframe with no trend monthly. Despite some mildly bullish signals from the OBV on both weekly and monthly charts, the overall technical picture remains weak. Over the past year, PAVmed has significantly underperformed the S&P 500, with a return of -74.41% compared to the S&P's 17.14%....

Is PAVmed, Inc. overvalued or undervalued?

2025-09-20 18:03:22

As of 2 September 2025, the valuation grade for PAVmed, Inc. has moved from fair to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued based on its current metrics, particularly with a Price to Book Value of 0.23, an EV to EBIT of -0.43, and an EV to EBITDA of -0.44. In comparison to peers, Delcath Systems, Inc. is considered expensive with a P/E of 68.06, while Neuronetics, Inc. has a risky valuation with a P/E of -5.11, highlighting PAVmed's relatively better positioning. Despite the attractive valuation, PAVmed has faced significant challenges, as evidenced by its stock performance, which has seen a staggering decline of 98.33% over the past five years compared to a 96.61% increase in the S&P 500. This stark contrast in returns underscores the potential mispricing of the stock, reinforcing the notion that it may be undervalued in the current market ...

View All News